Victory Capital Management
YMAB

Victory Capital Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Victory Capital Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-109,500
Closed -$597K – 2653
2023
Q3 		$597K Buy
109,500
+18,320
+20% +$107K ﹤0.01% 1912
2023
Q2 		$619K Buy
+91,180
New +$683K ﹤0.01% 1897
2022
Q4 		– Sell
-32,990
Closed -$476K – 2723
2022
Q3 		$476K Buy
+32,990
New +$546K ﹤0.01% 2075
2020
Q2 		– Sell
-8,512
Closed -$222K – 3316
2020
Q1 		$222K Buy
8,512
+3,220
+61% +$93.5K ﹤0.01% 2302
2019
Q4 		$165K Buy
5,292
+3,506
+196% +$104K ﹤0.01% 2367
2019
Q3 		$47K Buy
+1,786
New +$45.6K ﹤0.01% 2718

Other funds holding YMAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Victory Capital Management's YMAB Position: Q4 2023 in Review

Victory Capital Management sold out of Y-mAbs Therapeutics (YMAB) in Q4 2023, closing a stake of 109,500 shares — an estimated $597K sold.

Victory Capital Management first reported a position in YMAB in Q3 2019 and held it in 6 quarters. The position peaked at $619K in Q2 2023. 94 funds tracked by Wall St. Rank hold YMAB as of Q4 2023.

  • Victory Capital Management reported no remaining Y-mAbs Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Victory Capital Management sold 109,500 Y-mAbs Therapeutics shares in Q4 2023, an estimated $597K.
  • Victory Capital Management first reported a position in Y-mAbs Therapeutics in Q3 2019 and held it in 6 quarters.
  • Victory Capital Management's Y-mAbs Therapeutics position peaked at $619K in Q2 2023.
  • 94 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q4 2023.

Based on Victory Capital Management's 13F filing for Q4 2023, filed 5 Feb 2024.